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INTRODUCTION 
 Bile is secreted from the hepatocyte and it is essential for lipid 
metabolism, excretion of xenobiotic, and cholesterol homeostasis. Bile 
secretion depends upon the formation of bile acids in hepatocyte and its 
canalicular secretion.Once secreted in to the bile duct, bile enters the small 
bowel through the ampulla of water during the digestion phase. Bile stored 
inside the gall bladder during inter- digestive phase. After reaching the 
small bowel, the bile acid isabsorbed in the terminal ileum, and 
undergoesthe enterohepatic cycling. This happens 5-6 times per day and 
maintains the bile acid pool. This is essential to maintain the normal liver 
function. 
 Gall stones are formed when ever alteration in the chemical 
composition. Disturbance in bile acid formation,canalicular secretion and 
intestinal transport leads to gall stone formation.so it is important to 
identify hepatic, biliary, and intestinal bile acid transporters in the bile 
formation and secretion. 
 Gall stones divided into three types: 
1) Cholesterol Stones, 
2) Pigment Stones-(black) 
3) Pigment Stones - (brown) 
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Cholesterol stones are more common in north India in compare with 
southern India where pigment and mixed stones are common. Most of the 
gall stones are asymptomatic in presentation. 
The exact role of genetics in the formation of gallstones still not 
understood. The prevalence varies between the ethnic groups.  
 ABCB4 – encoding for the ATP-binding cassette, member of MDR3. 
It mediates the efflux of phospholipids from hepatocytes into canaliculi 
mainly the phosphatidylcholine [PC] into the bile. The function of 
phospholipid excretion is to protect the cell membrane from toxic bile 
saltsin the biliary tree.When function isdefective, it produces the spectrum 
of disorders, ranges from cholestasis, Cholelithiasis, Intrahepatic 
Cholestasis of Pregnancy, Ductopenia, and Cirrhosis. 
 So when ever other risk factors exclude for the formation of gall 
stone disease still the possibility of genetic transporters defect. 
 When mutation occurs at ABCB4 gene, causes the low phospholipid 
and high lithogenic bile. 
 Hence in this study we are looking for the prevalence of mutations 
in MDR3/ABCB4 gene in young patients with Cholelithiasis. 
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AIM OF THE STUDY 
To study and analyze the clinical profile, association of mutations in 
the MDR3/ABCB4 in young patients age less than 40 years with 
Cholelithiasis 
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REVIEW OF LITERATURE 
Liver is the largest organ of the body compressing of one fifth of 
total weight about 1200-1500 gms. Liver has dual blood supply receives 
70% of blood supply from portal vein, 30 % receives from hepatic artery. 
Has two lobes and eight segments depends upon the distribution of blood 
supply. 
Histology of liver 
 The hepatocytes arranged in plates with one to two cell thicknesses. 
They are separated by the sinusoids. Portal tract contains the branches of 
portal vein, hepatic artery, and bile duct. 
The bile formed in the hepatocyte is excreted through the canaliculi. 
These canaliculi have no wall and lined by tight junction of hepatocytes. 
This drain into intra lobular canalicular network, canals of Hering then into 
interlobular bile duct, small, medium, large bile duct .The right and left 
hepatic duct unite and forms the common hepatic duct, it joins with cystic 
duct and forms the common bile duct. 
The bile ducts are lined by cholangiocytes. The functions of 
cholangiocytes include modification of bile, secretion of water and 
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electrolytes, absorption of the bile acids and plays major role in chole -
hepatic shunt pathway. 
Bile is a complex solution, osmolality similar with plasma, 
composed with water, electrolytes, bile acids, phospholipids bile pigments, 
and cholesterol. 
About 500-600 ml of bile secreted each day. A major constituent is 
bile acid. It is actively secreted into the canaliculus. When bile acid 
secreted, it is actively induces the secretionof other solutes like 
phospholipids and cholesterol .Bile flows down into the gall bladder and 
stores there. When meal reaches the duodenum ,it is stimulatesthe release 
of cholecystokinin which cause the contractionof gall bladder and release 
of stored bile1and facilitates the absorption of cholesterol and reaches the 
ileum and absorbed through the ileal transporters and returned back to the 
portal circulation and enters into the liver1. 
Functions of bile acids  
 1. Digestion of lipids, cholesterol metabolism and fat soluble 
vitamins 
 2. Maintains the antimicrobial defense in the gut by forming the fat 
micellar complex2. 
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 3. Itprevents formation of calcium gall stonesand oxalate kidney 
stones3 
 4. Regulate the entero hepatic circulation 
Bile synthesis 
Bile acids synthesized from cholesterol from two pathways, the 
classic pathway and the alternate pathway. The primary bile acids 
composed of cholic acid and chenodeoxy cholic acids, which conjugate 
with glycine andtaurine, produce the secondary bile acids, to enhance the 
soluble nature of the bile acids.Endogenous bacterial flora present in the 
colon deconjugates the bile and the bile acids are absorbed in to the 
circulation. 
Composition of Hepatic Bile6 
COMPONENT CONCENTRATION 
Electrolytes and minerals (mmol/L):   
 Sodium 140-160 
 Potassium 3-8 
 Chloride 70-120 
 Bicarbonate 20-50 
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COMPONENT CONCENTRATION 
 Calcium 1-5 
 Phosphate 0-1.2 
 Magnesium 1-3 
Metals (?mmol/L):   
 Iron 2-72 
 Copper 12-21 
Organic constituents (mmol/L):   
 Bile acids 5-50 
 Bilirubin (total) 1-2 
 Phospholipid (lecithin) 0.5-20.0 
 Cholesterol 0.5-1.0 
 Glutathione 3-5 
 Glucose 0.2-1.0 
 Urea 2.2-6.5 
 Protein (g/ld.) 0.2-3.0 
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Composition of bile acids 
 
HEPATIC BILEACID TRANSPORT  
 The Hepatocyte and the Cholangiocyte areinvolved in the formation 
of bile. The hepatocellular movement of bile occurs via following three 
mechanisms. 
1. Primary ATP dependent, 
2. Secondary Sodium Gradient dependent,  
3. Tertiary OH-or HCO3 dependant.4 
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Active secretion of organic and inorganic solutes followed by 
passive movement of water and electrolytes occurs during production of 
bile.  
There are two types of bile flow into canaliculi 
1. Bile acid dependent bile flow 
2. Bile acid independent bile flow 
Primary solutes-actively pumped are conjugated bile acids, conjugated 
bilirubin, glutathione, and heavy metals. 
Secondary solute-water plasma, electrolytes,glucose, and amino acids 
Chole-hapatic shunt pathway The unconjugated bile acids secreted into 
the bile absorbs into the bile duct epithelial cells and periductular plexus 
and resecreted into the bile. This absorption generates a bicarbonate anion 
leads to bicarbonate rich bile acid secretion5. 
BILE ACID TRANSPORT PROTEINS 
 They are present in human hepatocyte,cholangiocyte,ileal 
enterocyte,and renal proximal tubule.The hepatocyte and sinusoidal 
membrane expressthe specialized transport protein for various compounds. 
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HEPATIC AND CHOLANGIOCYTE TRANSPORTERS 
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BILE ACID SECRETION DEPENDENT TRANSPORTERS. 
Transporter  Site Function  
NTCP Basolateral  Na + dependent bile 
acid/xenobiotic uptake 
OATP Basolateral Na + in dependent bile 
acid/xenobiotic uptake 
Na +k+ ATPase Basolateral Secretion of 2 Na for 3 K+ 
BSEP CANALICULAR  ATP dependent bile acid 
transport 
MDR3 CANALICULAR ATP 
dependentphosphatidylcholine 
transport 
ABCG8 CANALICULAR ATP DEPENDENT STEROL 
EXPORT 
FIC1 Canalicular ATP dependentamino 
phospholipid flipping 
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BILE ACID INDEPENDENT BILE FLOW-TRANSPORT 
PROTEINS  
MRP 2 Canalicular ATP dependent 
GLUCURONIDE,GLUTATHIONE,SULF
ATE CONJUGAES 
OATP BASOLATERAL NA+INDEPENDENT 
ORGANICANIONS,CATIONS, 
NEUTRAL STEROIS 
 
SINUSOIDAL BILE ACID EXPORT 
MRP 3 Basolateral ATP dependent export 
of bile acids and 
glucuronide conjugates
MRP4 BASOLATERAL ATP dependent export 
of glutathione & bile 
acids  
OSTα-OSTβ BASOLATERAL Bile acid export 
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CHOLANGIOCYTE/DUCTULAR SECRETION 
Aquaporin 1 (AQP1) Apical membrane Water transport 
Aquaporin 4 (AQP4) Basolateral membrane Water transport 
AE2 (SLC4A2) Apical membrane 
HCO3− secretion in 
exchange for Cl− 
CFTR (ABCC7) Apical membrane Cl− secretion  
ASBT (SLC10A2) Apical membrane 
Bile acid uptake 
(Chole-hapatic shunt 
 
ILEAL ENTEROCYTE 
ASBT (SLC10A2) Apical membrane 
Na+-dependent bile 
acid uptake  
NPC1L1 Apical membrane Sterol import 
OSTα-OSTβ Basolateral membrane Bile acid export 
MRP3 (ABCC3) Basolateral membrane Bile acid export 
 
80 %bile acids uptake is Na+ dependent and it is against 
concentration gradient. The driving force generated by NA+K+ATPase. It 
maintains the Na+ ion gradient mainly through the NTCP,which also 
responsible for the uptake of major drug like Rosuvastatin. Any 
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polymorphism in this gene is present asasymptomatic,because liver also 
express Na+ independent bile acid transporters. 
Rate limiting step in bile acid transport is canalicular secretion.In 
canaliculi, the bile acid concentration is more than 1000 fold as compared 
to concentration inthe hepatocytes. Bile acid secretion into the canaliculi is 
mediated through the MDR1 –multi drug resistance protein 1renames as 
Bile Salt Export Pump. Mutation in these results in progressive familial 
intra hepatic cholestasis type 2 characterized by biliary bile acid 
concentration <1%. 
INBORN ERRORS OF BILE ACID SYNTHESIS AND 
TRANSPORT7 
Defective Bile Acid Synthesis 
Primary defects 
Cerebrotendinous xanthomatosis (C27-steroid-27-
hydroxylase deficiency)  
Δ4-3-oxosteroid 5β-reductase (AKR1D1) deficiency 
C24-steroid-7α-hydroxylase (CYP7B1) deficiency  
α-Methylacyl-CoA racemase (AMACR) deficiency 
Secondary defects 
(due to organelle 
damage) 
Peroxisomal biogenesis disorders (PBDs) 
 Rhizomelic chondrodysplasia punctata 
 Zellweger spectrum 
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  Zellweger's syndrome 
  Neonatal adrenoleukodystrophy 
  Infantile Refsum's disease 
 Other 
  Hyperpipecolic acidemia 
  Leber's congenital amaurosis 
Disorders with loss of single peroxisomal function 
 Acatalasemia 
 Acyl-CoA oxidase deficiency 
 Adult Refsum's disease 
 D-bifunctional protein deficiency 
 Hyperoxaluria type I 
 Sterol carrier protein X deficiency 
 Thiolase deficiency (pseudo-Zellweger's 
syndrome) 
 X-linked adrenoleukodystrophy 
Contiguous gene syndrome 
Generalized hepatic synthetic dysfunction 
 Fulminant hepatic failure (multiple causes) 
 Neonatal iron storage disease 
 Tyrosinemia 
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Defective Bile Acid or Phospholipid Transport 
  
FIC1 (FIC1) deficiency: progressive familial 
intrahepatic cholestasis (PFIC) type 1:  
 Byler's disease 
 Benign recurrent intrahepatic cholestasis (BRIC) 
syndrome 
 Greenland familial cholestasis 
BSEP (ABCB11) deficiency: PFIC type 2  
MDR3 (ABCB4) deficiency: PFIC type 3  
Others 
  
 Alagille (Jagged) syndrome  
 Cholestasis-lymphedema syndrome (Aagenaes 
syndrome) 
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BILE ACID TRANSPORT DEFECTS 
There are various spectrum of disease are associated with mutation 
of these defects. Three important diseases in this spectrum are, familial 
intrahepatic cholestasis (FIC1) disease, bile salt export pump (BESP) 
disease, multi drug resistance protein 3 (MDR3) diseases. 
Familial intrahepatic cholestasis (FIC1) disease 
 This disease is caused by mutations in the ATP8B1gene; lead to 
progressive early-onset FIC1 disease (PFIC type 1).It typically shows a 
bland canalicular cholestasis, with varying degrees of hepatocellular 
ballooning and giant cell transformation; portal fibrosis and eventually 
cirrhosis. 
BSEP disease 
  This disease is caused by a wide spectrum of mutations in the 
ABCB11 gene. Patients will presents with high serum bile acid levels, but 
low or low-normal serum GGTP levels, nonspecific giant cell hepatitis on 
routine histology, increased risk of developing malignancies of the 
hepatobiliary system, such as hepatoblastoma, hepatocellular carcinoma, 
and cholangiocarcinoma, in contrast to patients with other forms of 
progressive intrahepatic cholestasis. 
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MDR3 disease 
 MDR3 deficiency is leads to decreased excretion of cytoprotective 
biliary phospholipids and causes leaving an increased pool of cytotoxic 
biliary bile salts. This can leads subsequent bile duct damage and 
proliferation. 
This disease caused by mutations in the ABCB4 gene that encodes 
the MDR3 glycoprotein. This helps translocate phospholipids into 
canalicular membrane.Present with several disease like PFIC type 3, 
intrahepatic and gallbladder lithiasis, intrahepatic cholestasis of pregnancy, 
and adult-onset ductopenic cholestatic liver disease8. 
 This mutations act as modifiers in disease like primary sclerosing 
cholangitis, primary biliary cirrhosis, and drug-induced cholestasis. 
PFIC -3 has high levels of serum GGTP and bile acids, and bile 
ductular proliferation on routine microscopy. 
 In female patients with familial intrahepatic cholestasis of pregnancy 
showed heterozygous mutation in this gene. 
The mutations likely lead to a genetic predisposition that requires 
the coexistence of other nongenetic factors for full expression of the 
disease 
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Pathogenesis of gall stones 10 
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The Role of Liver, Gallbladder And Intestine In Cholelithiasis9
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Risk factors for gall stones10 
Modifiable  Non modifiable 
Obesity 
• Rapid weight loss 
• Diet, 
• Alcohol abstinence 
• Decreased physical activity 
• Smoking 
• Medications (octreotide, 
ceftriaxone) 
• Hyperlipidemia 
• Diabetes mellitus type 
Female Gender 
• Age 
• Genetics 
 
In small percentage of people where all other risk factors are 
eliminated, the genetics plays a major role in the formation of gall stones. 
The biliary secretion of lipids appear important initial step the formation of 
gall stones.so when these defects are present they are the high risk patients 
to recurrent symptoms and it is important to identify these subgroup of 
patients and surveillance for the further developments of disease spectrum 
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 The genetic involvement in this group of patients varies with 
different ethnicity10.The highest prevalence seen in prima tribe of Arizona 
73 % of women >25 years have gall stones with prevalence raises 90 % 
in>60 years11. In Europe highest in Norway -21%, lowest in Italy-6% 
 In northern India- 6% with the increased consumption of Western 
diet increase of this prevalence can occur12. 
Functional characters of ABCB4 gene14 
The gene studied in mice that ,the wild type mice do excrete 
considerable amount of phospholipid as compared the mice with disrupted 
gene do not excrete phospholipid 13.ABCB4 is predominantly express in 
the liver small amount excreted in adrenal gland, muscle, testis, eye and 
placenta. 
 De Vree et al showed that here is a generalized bile acid reduction 
when function of ABCB4 decreased 16. 
The canalicular membrane has to tolerate very high 
concentratedetergent actions of bile salts well above the critical micellar 
concentration. Thiscan leads to solubilization of membranes17. Protective 
effect mediates through the transport of phospholipid through the 
canalicular membrane by via ABCB4 leads to reduction in concentrated 
bile acids and reduces the amount of injury. 
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When the patients treated with UDCA, the ABCB4 gene mRNA 
levels are not increased, but the level of ABCB4 protein level is increased 
by post translational modification15. 
Hypothetical lipid excretion at canaliculi14 
 
Canalicular lipid transport defects can cause gallstone formation. 
Because the solubilization the amount of bile salt and phospholipids 18. In 
ABCB negative mice the absence of phospholipid excretion leads to 
development of gall stones 19. So in patients with ABCB4 mutations are 
more prone to develop gall stone formations. 
Predictors of mutations in ABCB4 in patients with Cholelithiasis are 
symptoms reoccur after surgery, age <40 years, intra hepatic hyper echoic 
material20. 
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 When analyzing the mutations present in ABCB4 gene, 
GOTTHARDT, RUNZ, ET AL 8 demonstrated in familial cases of 
cholestasis the highest lod score region of chromosome number 7. 
 
Olivier Rosmorduc et al21 done ABCB4 gene sequencing, of exons 2 
to 28 and all splice junctions in patients with Low phospholipid associated 
Cholelithiasis and found identified 14 heterozygous and homozygous 
pointMutations . 
LANG ET AL22 identified several polymorphism in the ABCB4 
gene, done in various ethnicgroups consists of Caucasians, Korea, 
andJapanic populationsin both exon and intron of ABCB4 gene. 
Dario DE GiorgioET a23l identified 25 new mutations in the ABCB4 
gene in patients presented with progressive intrahepatic cholestasis, 
showed a cluster in the exon 17. As in our study we decided to study the 
exon 17 of ABCB4 gene in youngpatients less than 40 years presented 
with Cholelithiasis. 
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MATERIALS AND METHODS 
STUDY CENTER 
 Department of Medical Gastroenterology Madras Medical College 
& Rajiv Gandhi Government General Hospital, Chennai,and Institute of 
Basic Medical Sciences,Madras University, Taramani,Chennai 
DURATION OF STUDY 
 From April-2012 to Feb -2013 
SAMPLE SIZE 
 20 
INCLUSION CRITERIA 
 Patients meeting the following  
1. Age less than 40 years 
2. Cholelithiasis, choledocholithiasis 
3. Cholangitis, calculus cholecystitis, acute pancreatitis 
4. Intra hepatic biliary sludge 
5. Family history of gall stones 
6. Post cholecystectomy pain syndrome  
7. Intra hepatic cholestasis of pregnancy 
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EXCLUSION CRITERIA 
1. Age more than 40 years 
2. Hemolytic disorder 
3. Auto immune disorder 
4. Wilsons disease 
5. Obesity 
6. Metabolic Syndrome 
7. NAFLD 
8. Alcoholic liver disease 
SAMPLE COLLECTION: 
5 ml of peripheral blood was obtained by direct vein puncture using 
disposable syringe from each subject. The samples were immediately 
transferred into EDTA containing centrifuging tubes. The tubes were kept 
in ice box and transferred immediately to the laboratory. The buffy coat 
was separated and stored at –20°C until isolation of DNA was done. Blood 
samples recruited for the study was collected from young patients with 
Cholelithiasis referred to Department Of Medical Gastroenterology, 
Madras Medical College, and Chennai.  
 Prior ethical permission was obtained from the ethical committee 
and blood sample was collected from each patient after a well-informed 
structure of the study. The relevant clinical details was also collected and 
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tabulated and the samples were grouped based on their clinical status. The 
isolated from the blood samples sentto analysis for the presence of Single 
Nucleotide Polymorphisms (SNP) in the ABCB4 gene. 
DNA ISOLATION AND PURIFICATION: 
The phenol chloroform method of DNA isolation was used in this 
study. This frequently used method for DNA isolation removes proteins 
and other cellular components from nucleic acids, resulting in relatively 
pure DNA preparations.  
Principle: 
The concept of isolation of DNA is that all the other components of the 
cell and chromatin are removed using suitable methods to leave behind the 
DNA. In general the isolation of DNA from mammalian tissues follows 
four different steps. 
1. Lysis of cells with a detergent like sodium dodecyl sulphate (SDS). 
2. Digestion of proteins with enzymes (Proteinase – K). 
3. Extraction of DNA by phenol chloroform method.  
4. Precipitation of DNA with 100% ethanol.
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Reagents and their Functions: 
1. RBC Lysis Buffer 
Ammonium chloride – 155mM (8.29g) 
EDTA   – 0.1mM (1.00g) 
NaHCO3  – 12mM (0.034g) 
Adjust pH to 7.4 with 1M HCl or NaOH; make up to 1000ml with 
distilled water. Autoclave and store at room temperature. The RBC Lysis 
buffer is used to lyse the erythrocytes. 
2. SE Buffer/WBC Lysis Buffer 
Na2EDTA – 25mM (8.41g) 
NaCl  – 200mM (11.69g) 
  Adjust pH to 8.0 with 1M NaOH; make up to 1000ml with distilled 
water, autoclave and store at room temperature. 
3. Proteinase K (10 mg/ml) 
Dissolve 100mg Proteinase K in 10ml distilled water at room 
temperature and store it at -20°C. Proteinase K is the enzyme commonly 
employed for digestion of proteins. It is a highly active protease purified 
from the mold Tritirachium album.  
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3. Sodium dodecyl sulphate (SDS) 10% 
SDS - 10 gram 
With 10gram of SDS add distilled water to make up to 100 ml, stir 
on a magnetic stirrer, filter and store at room temperature. Do not 
autoclave. SDS is the commonly used detergent for DNA isolation. It 
ruptures the cell wall and nuclear membranes to release the contents. 
Furthermore, it also denatures proteins present in the sample. 
4. Phenol (Saturated, pH 8) 
Phenol is used to extract the DNA from the solution. In alkaline pH 
it extracts the DNA to the aqueous phase, which is collected for further 
purification. This will prevent the contamination of DNA with RNAs. In 
neutral or acidic pH phenol extracts RNA to aqueous phase. Hence, the pH 
of phenol is very important for this step. The pH of phenol should be 
maintained above 7.8 as all eukaryotic RNA with poly-A tails dissolve in 
alkaline phenol but in the acid range the DNA will partition into organic 
phase.  
5. Phenol: Chloroform: Isoamyl alcohol mixture 
To prepare Phenol: Chloroform: Isoamyl alcohol mixture, mix 25 
parts of Phenol, 24 parts of Chloroform and 1 part of Isoamyl alcohol. 
30 
 
The denaturation of proteins is mainly achieved through the activity 
of chloroform. It causes surface denaturation of proteins and also helps in 
removal of fats from the sample. Chloroform also eliminates any traces of 
phenol. Because phenol cause phosphodiester breakage, andalso useful for 
the removal of protein from nucleic acid samples. 
Due to the presence of proteins cause more chance of foaming in the 
solution at the time of phenol: chloroform extraction.This can be reduced 
by addition ofIsoamylalcohol and to maintain the stability of layers after 
centrifugation of deproteinised solution. 
6. Absolute ethanol 
The action of 100% ethanol is to precipitate the DNA leaving debris 
RNA and polysaccharides in the solution. 
7. 70% Ethanol 
Ethanol   - 70 ml 
Distilled water  - 30 ml 
It removes residual salt and moisture in the precipitated DNA. 
8. Tris-EDTA Buffer (pH - 8.0) 
Tris base  - 1.2114 gram 
EDTA  - 0.0372 gram 
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 This dissolved in 900 ml distilled water. Adjust the pH to 8. made up the 
volume to 1000 ml. Filter it , autoclave & store at 4oC. This is an ideal 
buffer to store the DNA. 
Procedure: 
1. 5ml of whole blood was taken and spun at 3500rpm for 20min at 
25°C.  
2. Buffy coat was removed carefully and transferred to a new 2.0 ml 
eppendorf tube.  
3. 1ml of 1X RBC lysis buffer was added to the buffy coat, vortexed, 
mixed well. Incubated for 15 min at 37°C, followed by a spin at 
3500 rpm for 15 min at room temperature.  
4. The supernatant was discarded, the pellet was dislodged and washed 
2 or 3 times with 1ml RBC lysis buffer (repeat of step 3) until a half 
white pellet appears. 5. The pellet was then dislodged by tapping 
to which 500μl of SE (WBC lysis) buffer, 5μl Proteinase K (final 
concentration 50μg/ml) and 25μl of 10% SDS (final concentration 
0.5%) was added and incubated in water bath at 37°C for overnight 
or 55°C for 3 hours.   
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6. Equal volume of Phenol: Chloroform: Isoamyl alcohol (25:24:1) to 
the lysate was added and intensely mixed well by inverting the tube 
until it turns to milky white in colour. 
7. The samples were spun at 10,000 rpm for 15min at room 
temperature.  
8. The upper aqueous phase alone was carefully collected with the help 
of wide bore tips without disturbing the other layers and transferred 
to a new tube.  
9. 2.5 volume of cold absolute ethanol was added to this aqueous phase 
and the tubes were inverted gently for several times. The DNA was 
found to be visible like a thread and assumed the shape of a cotton 
ball.  
10. The DNA was transferred to an eppendorf tube already containing 
1ml of 70% ethanol and spun at 12,000g for 10 min at 4°C.  
11. Supernatant was discarded and the pellet was air-dried in a sterile 
place for 3 hours to remove any trace of residual ethanol.  
12. Appropriate amount of 1X TE was added according to the size of the 
pellet, allowed to dissolve and stored at 4°C. 
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QUALITY CHECK AND QUANTIFICATION OF DNA 
The integrity of the DNA was assessed by running it on 0.7% 
Agarose gel. Further the quantification and quality check of DNA was 
performed by subjecting the DNA to spectrophotometry. The concept of 
quality check of DNA is to find out the purity of the extracted DNA. The 
extracted DNA may contain impurities like phenol, proteins and others. 
Principle for Agarose gel electrophoresis 
The integrity of the DNA is checked by Agarose gel electrophoresis. 
When the DNA is mixed with loading dye and run electrophoretically on 
0.7% Agarose gel in TAE buffer, the good high molecular weight DNA 
will appear as sharp band without smearing. 
Reagents 
1. TAE buffer (10x) 
Tris base    - 48.4 gram 
Glacial acetic acid  - 11.42 ml 
0.5 M EDTA (pH 8.0) - 20 ml 
Distilled water to make up to 1000 ml. Autoclave and store at room 
temperature. 
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2. Gel loading dye – Type III (6x) 
Bromophenol blue   - 0.25% (w/v) 
Xylene cyanol FF  - 0.25% (w/v) 
Glycerol in water  - 30% (v/v) 
Stir well in and store at 4oC. 
3. Ethidium bromide 
Ethidium bromide  - 10 mg 
Distilled water   - 1 ml 
Mix well to ensure that the dye has dissolved completely. Wrap the 
tube in aluminum foil and store at room temperature. 
Procedure 
1. 0.7% Agarose Gel preparation 
i. 0.7 gram of Agarose was weighed and transferred into a 250 ml conical 
flask. 
ii. 100 ml of 0.5x TAE buffer was added to it, stirred well and melted on a 
magnetic stirrer cum hot plate until the Agarose dissolves completely. 
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iii. The appropriate sized gel tray and comb was washed and wiped with 
70% Ethanol. The gel tray was placed inside the casting unit. The comb 
was placed on the gel tray and left on an even surface. 
iv. After the Agarose cools down to hand bearing temperature, 5μl of 
ethidium bromide was added and mixed well. It was poured on the gel 
tray and allowed to polymerize. After polymerization the comb is 
removed gently. 
2. Preparation of sample and loading 
i. The gel tray was removed from the casting unit and the tray placed in 
the electrophoresis tank. 
ii. 0.5x TAE buffer was poured into the tank until the gel gets immersed.  
iii. 2μl of each DNA sample was taken and mixed with 2μl of 6x loading 
dye and 8ml of sterile double distilled water. 
iv. The DNA samples were loaded into the wells. 
v. The electrodes were connected. 
vi. The power was switched ON, set at 100 V. 
vii. As the DNA is negatively charged, it will migrate towards the anode. 
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3. Visualizing the DNA 
i. When the bromophenol blue dye was in the middle of the gel, the 
power was switched OFF. 
ii. The gel was taken to the transilluminator and observed under UV and 
documented. 
iii. The good high molecular weight DNA will appear as sharp band 
without smearing.  
 Procedure for spectrophotometry 
The nucleic acid sample was analysed at 260nm and 280nm by 
using Nanodrop Spectrophotometer (Thermo scientific, Germany). The 
concentration and purity of the sample was analysed using the following 
formula, 
Concentration of DNA 
 Concentration of double stranded DNA sample (μg/μl) = A260 x 50 
Purity of DNA 
 Pure DNA = A260 /A280 ≥ 1.8 
 < 1.8 indicates protein and phenol contamination. 
 > 2.0 indicates the possible contamination with RNA. 
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 DNA DILUTION  
After confirmation for the presence of genomic DNA in the sample 
and quantification, the sample has to be diluted with autoclaved sterile 
double distilled water, to make it amenable to be used in polymerase chain 
reaction. The amount of DNA needed for PCR is 50-100 ng of DNA for a 20 
μl reaction mixture. 
Once a working DNA sample has been prepared, it was run in 1% 
agarose gel electrophoresis, observed under UV and documented. 
POLYMERASE CHAIN REACTION 
Principle 
PCR entails enzymatic amplification of specific DNA sequences 
using two oligonucleotide primers that flank the DNA segment to be 
amplified. n of large quantities of a specific DNA sequence took a leap 
forward with the development of the PCR. The PCR requires two 
nucleotide oligomers (Primers) that hybridize to the complimentary DNA 
strands in a region of interest. The method relies on thermal cycling, - of 
cycles of repeated heating and cooling done for DNA melting & enzymatic 
replication of the DNA. 
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 Reagents  
1. 10x PCR buffer (Applied Bio systemsInc. - ABI., USA)  
2. 25 mM MgCl2 (ABI., USA) 
3. 2.5mM dNTP Mix (Takara, Japan) 
4. Primers (Sigma Aldrich, India) 
 Preparation of the primer 
The primer is obtained as lyophilized powder and is reconstituted 
in appropriate volume of sterile triple glass distilled water to a 
concentration of 100µM. A working stock of 2µM primer is prepared and 
stored at -20°C.  
The primers used in this study are as follows: 
Primer 
Name 
Sequence (5’Æ3’) Length(bp) 
Tm 
(°C) 
GC 
(%) 
ABCB4 
ex17 F 
GAGGCCAGAATAGGGACGGGC 21 60 67 
ABCB4 
ex17 R 
GAGGTTGGGAGAAGCAGCAGC 21 58 62 
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Taq DNA polymerase(Applied Biosystems, USA) 
It is a highly thermo stable DNA polymerase of a thermophilic 
bacterium Thermus aquaticus. 
Procedure 
i. 2μl of genomic DNA (100ng/µl) was pipetted directly to the bottom 
of the labeled PCR tubes.  
ii. A master mix of all the components of PCR except the genomic 
DNA was prepared as follows: 
CONTENTS 
STOCK 
CONCENTRATION
FINAL 
CONCENTRATION 
(50μl) 
QUANTITY
PCR Buffer 10X 1X 5.0μl 
MgCl2 25mM 2.5mM 5.0μl 
dNTP mix 2.5mM 100μM 2.0μl 
Forward 
Primer 2μM 80nM 2.0μl 
Reverse 
Primer 2μM 80nM 2.0μl 
Taq DNA Pol 5U/μl 1U/Rxn 0.2μl 
Distilled water - - 31.8μl 
Genomic 
DNA 100ng/μl 200ng/10μl 2.0μl 
Total   50.0 μl 
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Thermal cycle protocol 
The PCR mix was added into a sterile 0.2ml PCR tube and the 
following thermal cycle condition was programmed in GeneAMP® PCR 
System 9700-Applied Biosystems, USA. 
PCR thermal cycle 
 
After completion of the programme, the samples were tested for 
amplification by 1.5% agarose gel electrophoresis. We can visualize with 
ethidium bromide. 
The polymerase chain reaction product yields an amplicon of size 
475 bp 
  
94°C
5 mins
94°C
30 secs
60°C
30 secs
72°C
45 secs
72°C
7 mins
10°C
∞
40 
cycles
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GENOTYPING BY DIDEOXY SEQUENCING 
Sequencing is a quick and flexible genotyping technique. This 
strategy is used to identify and confirm the presence of heterozygous single 
nucleotide polymorphisms within a genomic region of interest. The PCR 
products were sequenced commercially. (Macrogen Inc. Seoul) The 
protocol followed by them is as follows 
Reagents 
• Agarose gel (1%) 
• BigDye Dilution Buffer (2.5x, Applied Biosystems) 
• BigDye Terminator v3.0 (Applied Biosystems) 
• dNTPs (10mM each) 
• Ethanol (80%) 
• Formamide (Optional) 
• Forward primer (2mM) 
• Genomic template DNA 
• PCR Buffer (10x, from supplier of Taq polymerase) 
• Precipitation mix – For 1 liter, mix 800ml of 96% ethanol, 16ml of Na 
Acetate (pH 5.5) and 158ml of MilliQ H2O 
• Reverse primer (2mM0 
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• Sequencing primer (2mM; one of the oligonucleotides used for PCR 
amplification can be used) 
• Taq polymerase (5U/μL) 
 Equipment 
• Apparatus for agarose gel electrophoresis 
• Capillary sequncer (Applied Biosystems 3730) 
• Plates are used to perform reactions 
• Sequence analysis software (Bio Edit) 
 Method 
1.  The PCR product was purified using a kit method.  
2.  The following dideoxy sequencing rection (5μL total volume) was 
prepared: 
• 1μL of diluted PCR product 
• 1μL of sequencing primer (2mM) 
• 0.2μL of BigDye terminator v 3.0 
• 1.8μL of 2.5x BigDye Dilution Buffer 
• 1μL of MilliQ H2O. 
3.  The following sequencing protocol was followed: 
 40 cycles of 92°C for 10 seconds followed by 50°C for 5 seconds and 
60°C for 120 seconds. 
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4.  Purified by adding 30μL of precipitation mix. 
5.  They were then vortexed for 15 seconds. 
6.  They were then centrifuged at 3500g for 40 minutes. 
7.  The supernatant was discarded (centrifuge plate upside down for 1 
minute at 32g). 
8.  The pellet was washed by adding 25μL of 80% ethanol. 
9.  They were then centrifuged at 3500g for 5 minutes. 
10. The supernatant was discarded (centrifuge plate upside down for 1 
minute at 32g). 
11. The pellet was air-dried or heated for 10-15 minutes at 80°C (until 
there is no smell of alcohol). 
12. The pellet was dissolved in 10μL of H2O or Formamide. 
13. The samples were analyzed on a capillary sequencer (Applied 
Biosystems 3730). 
14. The sequencing data was then analyzed using a suitable software 
package. 
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STEP NO: 1 
Genomic DNA Isolation from 19 patients in 0.7% Agarose gel from 
the patient’s blood placed in the test tube. 
 
 
       Fig No: 1GENOMIC DNA  
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STEP NO: 2 PCR amplicon of ABCB4 gene by electro phoresis 
Control 
  Patient no 1-12  
 
 
 
 
    13      L     14    15   16     17    18    19    20 
 
 
 
L                 1        3     4      5     6       7      8     9    10    11   12  
DNA not isolated in patient no: 2 
PATIENT NUMBER 13‐20
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Fig: 2 PCR Amplicons of ABCB4 gene exon 17 were electrophoresed 
on 2% Agarose gel. 
STEP NO: 3 - Matching With Primer Exon 17 of ABCB4 Gene 
 
 
 
EMBOSS_001         1 GAGGCCAGAATAGGGACGGGCtaagcatcccatgaaggttatttcttggc     50 
 
EMBOSS_001         1 --------------------------------------------------      0 
 
EMBOSS_001        51 cgaacaacccatactcagcttatgatgtgtaatcagtaaacattgttaac    100 
 
EMBOSS_001         1 --------------------------------------------------      0 
 
EMBOSS_001       101 atgttataatatactgtcctactctctagtagtttgcttgtcattctctg    150 
 
EMBOSS_001         1 --------------------------------------------------      0 
 
EMBOSS_001       151 cacctagtttgcgagtcccttgagggcaatggccatgccttttctatgtc    200 
 
EMBOSS_001         1 --------------------------------------------------      0 
 
EMBOSS_001       201 tacagactctggtaactgttgtgtcatcaccagtttgccctgatgtttat    250 
 
EMBOSS_001         1 --------------------------------------------------      0 
 
EMBOSS_001       251 atgttctaggaagcaaatgtgccaccagtgtcctttctgaaggtcctgaa    300 
                              ||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001         1 ---------gaagcaaatgtgccaccagtgtcctttctgaaggtcctgaa     41 
 
EMBOSS_001       301 actgaataaaacagaatggccctactttgtcgtgggaacagtatgtgcca    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001        42 actgaataaaacagaatggccctactttgtcgtgggaacagtatgtgcca     91 
 
EMBOSS_001       351 ttgccaatggggggcttcagccggcattttcagtcatattctcagagatc    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001        92 ttgccaatggggggcttcagccggcattttcagtcatattctcagagatc141 
 
EMBOSS_001       401 atagcggtaagtttgcaaacaccacataacagcctgaattagatcaattc    450 
                     ||||||                                             
EMBOSS_001       142 atagcg--------------------------------------------    147 
 
EMBOSS_001       451 atcaGCTGCTGCTTCTCCCAACCTC    475 
 
EMBOSS_001       148 -------------------------    147 
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DNA SEQUENCING OF 19 PATEINTS 
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INTRON 17 VARIANT--DIAGNOSED BY THYMIDINE 
REPLACED THE CYTOSINE AT 388-INTRON 17 OF 
CHROMOSOME NO 7 OF ABCB4 GENE 
  
HETEROZYGOUS ALLELE‐
HAS BOTH T AND C‐
SHOWED AS Y‐26 % OF 
PATIENTS 
HOMOZYGOUS ALLELE‐
PURE T EXPRESSION 
INSTEAD OF C—IN 68 % 
OF PATIENTS 
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DISCUSSION 
Biliary excretion of bile salts and other bile constituents from liver 
cells are mediated by the canalicular (apical) transporters P-glycoprotein 3 
(MDR3, ABCB4). So in this study we attempted to establish genetic 
variability in ABCB4 and Cholestasis. There are few published studies 
done in western population in which mutation and variation in ABCB4 
gene has been studied  
Degiorgio et al., screened mutations in 68 PFIC3 cases and found 31 
mutations out of which 25 mutations were novel. The result of the study 
showed that the causative mutations were spread along 14 out of the 27 
coding exons. But prevalence was more common on exon 17. So we 
studied exon 17 of ABCB4 region for genetic variation. 
Low phospholipid associated Cholelithiasis is characterized by the 
association of ABCB4 mutations and low biliary phospholipid 
concentration 21. 
The primary function of biliary phospholipid excretion is to protect 
the membranes of cells facing the biliary tree against these bile salts. The 
uptake of Phosphadityl choline in bile salt micelles reduces the detergent 
activity of these micelles14. 
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The ABCB4 gene helps the efflux of phospholipid from hepatocyte 
into biliary canaliculi. When there is defect in function of ABCB4, it leads 
to production of bile low in the phospholipid which leads to increased 
lithogenicity21. ABCB4 is predominantly expressed in the liver and in 
small amount present in adrenal gland, muscle, testis, eye and placenta 
Defect in ABCB4 has been demonstrated initially in mice13. The 
wild type mice excrete more phospholipid as compared with mice with 
disrupted gene, which do not excrete phospholipid 13. 
De Vree et al demonstrated that there is a generalized bile acid 
reduction when function of ABCB4 is decreased in humans16. 
Olivier Rosmorduc et al21 published a  study in which he analyzed 
60 consecutive patients with symptomatic or complicated Cholelithiasis, 
ABCB 4 gene mutation   analysis was done in 32 patients meeting the 
following criteria - Age less  than 40 years, recurrent symptoms after 
cholecystectomy-the clinical phenotype of low phospholipid associated 
Cholelithiasis, and 28 patients post cholecystectomy status [not meeting 
the criteria ], 32 patients with chronic liver disease of varying etiology 
were taken as control.   18 patients presented with point mutation at 
ABCB4 locus,( in suspected clinical phenotype patients) and no mutation 
was seen in the other two groups. 
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Multivariate analysis done in these patients revealed that following 
factors predict the mutation. 
1.Age less than 40 years 
2.Recurrence of symptoms after cholecystectomy 
3.Intra hepatic hyper echoic foci 
In our study, we studied in 20 patients with with age less than 40 
years and symptomatic Cholelithiasis after cholecystectomy  
The male: female ratio is 1:4 in our study. Genomic DNA was 
isolated as per the procedure given and qualitative and quantitative 
analyses were done. Genomic DNA was electrophoresed in 0.7% agarose 
gel (Fig. 1). With the primer designed particularly to amplify exon 17 of 
ABCB4 gene, PCR product of 475bp was amplified and confirmed in 2% 
agarose gel (Fig. 2) the amplified PCR product was out sourced for 
sequencing using forward primer. The sequence result was analyzed using 
Bio edit software and multiple alignment of sequence all patient along with 
the reference sequence (NG_007118.1) from the NCBI 
(http://www.ncbi.nlm.nih.gov/nuccore/NG_007118.1)  is shown in result. 
No variations were observed in the exon 17 region of ABCB4 gene in the 
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patients studied.(Fig. 3) An intronic variation in the region g.51576C>T in 
intron 17 was observed. (Fig. 4, 5) 
It is single nucleotide polymorphism at intron 17-68 % homozygous 
expression, 26 % -heterozygous expression, and absent in 5 %. As this 
variation is in intron region it does not directly affect the ABCB4 function. 
This is a protein –altering variants. This is predicted to have functional 
consequences like changes in the proteins and indirectly may leads to 
significant decrease in activity of ABCB4 gene. 
This finding is correlated with Thomas Lang et22 al study, who 
demonstrated similar mutation during the study of polymorphism of 
ABCB4 gene. This was a multi-centric study, and he did sequencing of 
159 DNA samples of Caucasian, African-American, Japanese, and Korean 
origin. He identified 76 polymorphism, among them 14 exonic 
polymorphism, 8 protein altering variant. They reported this variation 
g.51576C>T in intron 17 to be in 82.7%. 
On comparison we found that the mutation seen in our patients is 
similar to that of variant 37 mutation of Lang et al study. 
The clinical significance of these studies is that when this intronic 
mutation is present, the patient has recurrent biliary symptoms. These 
patients should be placed on lifelong Urso deoxy cholic acid to prevent 
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complications of cholestasis as UDCA renders bile composition less 
injurious. This protects the hepatocytes and the biliary epithelia24. UDCA 
also enhances ABCB4 protein levels 25, suggesting one another 
mechanism by which UDCA may benefits ABCB4 mutation carriers24 
This is the first Indian study to study the prevalence of ABCB4 gene 
mutations in patients with recurrent biliary symptoms. Larger studies are 
required to look into the prevalence of this mutation in our population, 
both in the healthy as well as those with disease. 
 In young patients with recurrent biliary symptoms after 
cholecystectomy, possible underlying genetic factors should be evaluated. 
These patients can benefit from medical management by Urso deoxy 
cholic acid therapy. 
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CONCLUSION 
This is first study to screen variations in ABCB4 gene in young 
patients with gall stones in India. Mutation can be spread along entire 
length of the gene. We could not find any mutation  in Exon 17 of ABCB4. 
Gene.An intronic variation in g.51576C>T in intron 17 was observed in 
our patients. 
This implies that this mutation can have functional defects in the 
action of proteins leading to lithogenic bile, larger studies covering all the 
exons of ABCB4 gene might throw more light in genetics of this 
transporter defects in Indian Population. 
If a mutation can demonstrated in these patients might benefitnfrom 
lifelong UDCA therapy decrease the lithogenicity of bile. 
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ABC -ATP-binding cassette 
AE2 chloride-bicarbonate anion 
exchanger isoform 2 
ASBT apical Na+ bile acid transporter 
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NAME AGE SEX DIAGNOSIS OGD  CBC FBS UREA CREAT TB PT/INR OTHER
JULIET 17 f  CALCULOUS CHOLECYNAD 7600/63/31/5 78 21 0.8 1.2 1.06 CBD STONE‐ERCP DONE
GUNA SUNDARI 17 f  CALCULOUS CHOLECYSTITIS 6300/61/36 109 18 0.7 0.8 1.01 NIL
PADMAVATHY 18 f  CALCULOUS CHOLECYSTITIS 8900/66/32 98 17 0.8 1.1 1.01 CBD STONE
KUMARI 18 f  CALCULOUS CHOLECYSTITIS 9100/64/32/3 89 24 0.9 1 1.04 NIL
GEETHA DEVI 21 f  CALCULOUS CHOLECYSTITIS 6400/61/30/1 78 23 0.8 0.8 1.06 ASTHMATIC
RAVI KUMAR 23 m  CALCULOUS CHOLECYSTITIS 7500/60/36 66 22 0.7 0.7 1.01 CBD STONE
RASIYA 23 f  CALCULOUS CHOLECYSTITIS 8700/63/32 80 21 0.8 0.9 1.01
INDIRA 24 f  CALCULOUS CHOLECYSTITIS 9800/66/35 78 18 0.9 0.8 1.04
VENKARARAMAIYA 24 m  CALCULOUS CHOLECYSTITIS 7800/68/34 109 17 1 1.1 1.1
ANJALIDEVI 25 f  CALCULOUS CHOLECYSTITIS 8900/67/37 98 24 1.1 1.2 1.1
BAGYALAKSHMI 26 f  CALCULOUS CHOLECYSTITIS 9500/64/33 98 23 0.8 1.2 1.1
VIDAVAREIYAR 26 m  CALCULOUS CHOLECYSTITIS 8900/62/34/3 89 22 0.7 1.3 1.1
MURUGANMMAL 26 f  CALCULOUS CHOLECYSTITIS 9100/64/32 78 24 0.8 1.1 1.06
JANSI RANI 27 F  CALCULOUS CHOLECYFUNDAL GA9800/52/37/10.6/B 89 34 0.9 0.8 1.07 AUDIOGRAM ‐HIGH FREQ HEARING LOSS
LAXMI NARAYANMMAL 27 f  CALCULOUS CHOLECYSTITIS 9500/64/33 88 22 1 0.9 1 CLD
ALI FATHIMA 28 f  CALCULOUS CHOLECYLAX LES 79OO/64/31 102 28 0.8 1.2 1.02 ASTHMATIC
HYARUNISHA 28 f  CALCULOUS CHOLECYSTITIS 7500/60/36 98 24 0.7 0.9 1.06
MAJITHA BANU 31 f  CALCULOUS CHOLECYSTITIS 8700/63/32 110 23 0.8 0.8 1.01
TER CHART 24 f  CALCULOUS CHOLECYSTITIS 9800/66/35 89 22 0.9 1.1 1.01
RANI 26 f  CALCULOUS CHOLECYSTITIS 7800/68/34 78 21 0.8 1.2 1.04
MASTER CHART
 
Your digital receipt
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information
regarding your submission.
Paper ID 311829772
Paper title PREVALENCE OF MUTATIONS IN MDR3/ABCB4 GENE IN YOUNGPATIENTS WITH CHOLELITHIASIS D
Assignment
title Medical
Author M.radha 16102504 D.M. Medical Gastroenterology
E-mail drradha0509@gmail.com
Submission
time 23-Mar-2013 02:20PM
Total words 6144
First 100 words of your submission
PREVALENCE OF MUTATIONS IN MDR3/ABCB4 GENE IN YOUNG PATIENTS WITH
CHOLELITHIASIS Dissertation submitted for D.M.DEGREE EXAMINATION- AUGUST-2013
BRANCH-IV-MEDICAL GASTROENTEROLOGY MADRAS MEDICAL COLLEGE & RAJIV GANDHI
GOVERNMENT GENERAL HOSPITAL CHENNAI-600003 THE TAMILNADU DR.M.G.R MEDICAL
UNIVERSITY CHENNAI-600032 Introduction Bile is secreted from the hepatocyte and it is essential
for lipid metabolism, excretion of xenobiotic, and cholesterol homeostasis. Bile secretion depends
upon the formation of bile acids in hepatocyte and its canalicular secretion. Once secreted in to the bile
duct, bile enters the small bowel through the ampulla of water during the digestion phase. Bile stored...
Copyright 2012 Turnitin. All rights reserved.
